share_log

Stifel Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $26

Benzinga ·  Oct 10, 2023 05:47

Stifel analyst Paul Matteis initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and announces Price Target of $26.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment